{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:05:00Z","timestamp":1781895900726,"version":"3.54.5"},"reference-count":67,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Hypopigmentation disorders pose significant diagnostic challenges in dermatology, sometimes reflecting underlying hematological conditions. This review explores the clinical presentations related to hypopigmentation in hematological disorders, focusing on vitiligo, morphea, and syndromic albinism. Vitiligo, an autoimmune disorder targeting melanocytes, involves interactions between genetic polymorphisms and immune responses, particularly regarding CD8+ T cells and IFN-\u03b3. Drug-induced vitiligo, notably by immune checkpoint inhibitors and small-molecule targeted anticancer therapies, underscores the importance of immune dysregulation. Morphea, an inflammatory skin disorder, may signal hematological involvement, as seen in deep morphea and post-radiotherapy lesions. Syndromic albinism, linked to various genetic mutations affecting melanin production, often presents with hematologic abnormalities. Treatment approaches focus on targeting the immune pathways specific to the condition, and when that is not possible, managing symptoms. Understanding these dermatological manifestations is crucial for the timely diagnosis and management of hematological disorders.<\/jats:p>","DOI":"10.3390\/hematolrep16020036","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:43:54Z","timestamp":1717577034000},"page":"354-366","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Skin Hypopigmentation in Hematology Disorders"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-2061","authenticated-orcid":false,"given":"Roberto","family":"Mazzetto","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Miceli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1985-0326","authenticated-orcid":false,"given":"Alvise","family":"Sernicola","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-7649","authenticated-orcid":false,"given":"Jacopo","family":"Tartaglia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Alaibac","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1523-1747.ep12324456","article-title":"In Vivo Destruction of Melanocytes by the IgG Fraction of Serum from Patients with Vitiligo","volume":"105","author":"Gilhar","year":"1995","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1084\/jem.158.1.246","article-title":"Antibodies to Normal Human Melanocytes in Vitiligo","volume":"158","author":"Naughton","year":"1983","journal-title":"J. Exp. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1468-3083.2012.04501.x","article-title":"Melanocyte Antigen-Specific Antibodies Cannot Be Used as Markers for Recent Disease Activity in Patients with Vitiligo","volume":"27","author":"Kroon","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaad.2003.12.031","article-title":"Topical Tacrolimus Therapy for Vitiligo: Therapeutic Responses and Skin Messenger RNA Expression of Proinflammatory Cytokines","volume":"51","author":"Grimes","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction Blistering the Lesional Skin of Vitiligo Patients Reveals Useful Biomarkers of Disease Activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.188.6.1203","article-title":"High Frequency of Skin-Homing Melanocyte-Specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo","volume":"188","author":"Ogg","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1523-1747.2001.01408.x","article-title":"Specific Cytotoxic T Lymphocyte Responses against Melan-A\/MART1, Tyrosinase and Gp100 in Vitiligo by the Use of Major Histocompatibility Complex\/Peptide Tetramers: The Role of Cellular Immunity in the Etiopathogenesis of Vitiligo","volume":"117","author":"Palermo","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients","volume":"129","author":"Konijnenberg","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","article-title":"Immunopolarization of CD4+ and CD8+ T Cells to Type-1-like Is Associated with Melanocyte Loss in Human Vitiligo","volume":"83","author":"Tigges","year":"2003","journal-title":"Lab. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","article-title":"CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Na\u00efve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment","volume":"24","author":"Edwards","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PPO.0b013e31824d4465","article-title":"Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma: Current Status and Future Outlook","volume":"18","author":"Wu","year":"2012","journal-title":"Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1126\/science.aaa1292","article-title":"Detection of Self-Reactive CD8+ T Cells with an Anergic Phenotype in Healthy Individuals","volume":"346","author":"Maeda","year":"2014","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41375-021-01210-8","article-title":"Safety and Efficacy of the BRAF Inhibitor Dabrafenib in Relapsed or Refractory Hairy Cell Leukemia: A Pilot Phase-2 Clinical Trial","volume":"35","author":"Tiacci","year":"2021","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2022017789","article-title":"A Phase 2 Clinical Trial of Combined BRAF\/MEK Inhibition for BRAFV600E-Mutated Multiple Myeloma","volume":"141","author":"Giesen","year":"2023","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.13585","article-title":"Drug Induced Vitiligo-like Depigmentation from a CDK 4\/6 Inhibitor","volume":"18","author":"Chan","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_17","first-page":"505","article-title":"The EGF Receptor\u2014An Essential Regulator of Multiple Epidermal Functions","volume":"10","author":"Jost","year":"2000","journal-title":"Eur. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/12034754211041610","article-title":"Reader Comment Regarding \u201cCutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management\u201d","volume":"26","author":"Sauder","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bjh.18096","article-title":"Imatinib-Induced Generalized Vitiligo","volume":"197","author":"Jain","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune Checkpoint Inhibitor\u2014Related Dermatologic Adverse Events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/12034754241230690","article-title":"Development of Vitiligo in Patients Treated with BRAF\/MEK Inhibitors: A Systematic Review","volume":"28","author":"Liu","year":"2024","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","article-title":"Pigmentary Changes in Patients Treated with Targeted Anticancer Agents: A Systematic Review and Meta-Analysis","volume":"77","author":"Dai","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10147-007-0746-y","article-title":"Efficacy and Safety Profile of Imatinib Mesylate (ST1571) in Japanese Patients with Advanced Gastrointestinal Stromal Tumors: A Phase II Study (STI571B1202)","volume":"13","author":"Nishida","year":"2008","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.alit.2021.08.005","article-title":"Drug-Induced Scleroderma-like Lesion","volume":"71","author":"Hamaguchi","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s100670050131","article-title":"Bleomycin-Induced Scleroderma: Report of a Case with a Chronic Course Rather Than the Typical Acute\/Subacute Self-Limiting Form","volume":"18","author":"Passiu","year":"1999","journal-title":"Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2133.2006.07597.x","article-title":"Taxane-Induced Scleroderma","volume":"156","author":"Itoh","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/ijd.17084","article-title":"A Case of Hypopigmented Mycosis Fungoides with Granulomatous Slack Skin","volume":"63","author":"Cui","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000330335","article-title":"Cutaneous Granulomas in Ataxia Telangiectasia and Other Primary Immunodeficiencies: Reflection of Inappropriate Immune Regulation?","volume":"223","author":"Chiam","year":"2011","journal-title":"Dermatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13816810802415256","article-title":"Uncommon Associations with Ataxia-Telangiectasia: Vitiligo and Optic Disc Drusen","volume":"30","author":"Sari","year":"2009","journal-title":"Ophthalmic Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0167-5699(96)80556-1","article-title":"IL-4-Induced Immune Deviation as Antigen-Specific Therapy for Inflammatory Autoimmune Disease","volume":"17","author":"Racke","year":"1996","journal-title":"Immunol. Today"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature12614","article-title":"Integrin-Modulating Therapy Prevents Fibrosis and Autoimmunity in Mouse Models of Scleroderma","volume":"503","author":"Gerber","year":"2013","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-Wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis","volume":"370","author":"Affandi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mazzetto, R., Miceli, P., Tartaglia, J., Ciolfi, C., Sernicola, A., and Alaibac, M. (2024). Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma. Life, 14.","DOI":"10.3390\/life14020245"},{"key":"ref_34","first-page":"667","article-title":"PUVA-Bath Photochemotherapy and Isotretinoin in Sclerodermatous Graft-versus-Host Disease","volume":"18","author":"Ghoreschi","year":"2008","journal-title":"Eur. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2011-03-341693","article-title":"A Phase 1 Study of Imatinib for Corticosteroid-Dependent\/Refractory Chronic Graft-versus-Host Disease: Response Does Not Correlate with Anti-PDGFRA Antibodies","volume":"118","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/37.12.1358","article-title":"Successful Treatment with Antithymocyte Globulin and Cyclosporin A of a Severe Aplastic Anaemia Associated with an Eosinophilic Fasciitis","volume":"37","author":"Bonnotte","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1046\/j.1365-2133.1998.02535.x","article-title":"Eosinophilic Fasciitis Associated with Low-Grade T-Cell Lymphoma","volume":"139","author":"Masuoka","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"ref_38","first-page":"343","article-title":"Lymph-Node-Based Malignant Lymphoma and Reactive Lymphadenopathy in Eosinophilic Fasciitis","volume":"318","author":"Naschitz","year":"1999","journal-title":"Am. J. Med. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Joly-Chevrier, M., G\u00e9linas, A., Ghazal, S., Moussa, S., McCuaig, C.C., Piram, M., Mereniuk, A., Litvinov, I.V., Osman, M., and Pehr, K. (2023). Morphea, Eosinophilic Fasciitis and Cancer: A Scoping Review. Cancers, 15.","DOI":"10.3390\/cancers15184450"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1108623","DOI":"10.3389\/fmed.2023.1108623","article-title":"Morphea: The 2023 Update","volume":"10","author":"Papara","year":"2023","journal-title":"Front. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Foti, R., De Pasquale, R., Dal Bosco, Y., Visalli, E., Amato, G., Gangemi, P., Foti, R., and Ramondetta, A. (2021). Clinical and Histopathological Features of Scleroderma-like Disorders: An Update. Medicina, 57.","DOI":"10.3390\/medicina57111275"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0190-9622(00)90233-0","article-title":"Scleroderma-like Reaction Induced by Uracil-Tegafur (UFT), a Second-Generation Anticancer Agent","volume":"42","author":"Kono","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mjd.2003.30","article-title":"Scleroderma-like Cutaneous Lesions Induced by Paclitaxel: A Case Study","volume":"48","author":"Kupfer","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaad.2001.07.001","article-title":"Gemcitabine-Associated Scleroderma-like Changes of the Lower Extremities","volume":"51","author":"Bessis","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-002-0635-8","article-title":"Diffuse Scleroderma Occurring after the Use of Paclitaxel for Ovarian Cancer","volume":"22","author":"Bugatti","year":"2003","journal-title":"Clin. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e15041","DOI":"10.1111\/dth.15041","article-title":"Radiation-Induced Morphea\u2014A Rare, but Not to Be Dismissed, Adverse Effect of Radiotherapy","volume":"34","author":"Gambichler","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1468-3083.2005.01200.x","article-title":"Multiple Myeloma with Scleroderma-like Changes","volume":"19","author":"Blanco","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1002\/ski2.189","article-title":"Paraneoplastic Scleroderma in Kaposi\u2019s Sarcoma: Report of Two Cases","volume":"3","author":"Belcadi","year":"2023","journal-title":"Skin Health Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized Scleroderma: Clinical Spectrum and Therapeutic Update","volume":"90","author":"Careta","year":"2015","journal-title":"An. Bras. Dermatol."},{"key":"ref_50","unstructured":"Litaiem, N., and Idoudi, S. (2024). StatPearls, StatPearls Publishing."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1024\/0301-1526.38.1.31","article-title":"Nephrogenic Systemic Fibrosis","volume":"38","author":"Vosshenrich","year":"2009","journal-title":"Vasa"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2022.12.024","article-title":"Chronic Graft-versus-Host Disease. Part I: Epidemiology, Pathogenesis, and Clinical Manifestations","volume":"90","author":"Baumrin","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","article-title":"Sclerotic-Type Chronic GVHD of the Skin: Clinical Risk Factors, Laboratory Markers, and Burden of Disease","volume":"118","author":"Martires","year":"2011","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11882-012-0241-z","article-title":"Clinical Overview of Cutaneous Features in Hypereosinophilic Syndrome","volume":"12","author":"Aigner","year":"2012","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_55","first-page":"78","article-title":"Paraneoplastic Scleroderma: Are There Any Clues?","volume":"24","author":"Jedlickova","year":"2016","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.17275","article-title":"Management of Albinism: French Guidelines for Diagnosis and Care","volume":"35","author":"Dufresne","year":"2021","journal-title":"Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/pcmr.12982","article-title":"Genetics of Non-syndromic and Syndromic Oculocutaneous Albinism in Human and Mouse","volume":"34","author":"Hayashi","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V78.1.51.51","article-title":"Treatment of Hemophagocytic Lymphohistiocytosis with Chemotherapy and Bone Marrow Transplantation: A Single-Center Study of 22 Cases","volume":"78","author":"Blanche","year":"1991","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1750-1172-8-168","article-title":"Clinical, Laboratory and Molecular Signs of Immunodeficiency in Patients with Partial Oculo-Cutaneous Albinism","volume":"8","author":"Dotta","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.0105-2896.2010.00890.x","article-title":"Inherited Defects in Lymphocyte Cytotoxic Activity","volume":"235","author":"Schmid","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wiriyasermkul, P., Moriyama, S., and Nagamori, S. (2020). Membrane Transport Proteins in Melanosomes: Regulation of Ions for Pigmentation. Biochim. Biophys. Acta (BBA)-Biomembr., 1862.","DOI":"10.1016\/j.bbamem.2020.183318"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13023-014-0132-6","article-title":"Towards the Targeted Management of Chediak-Higashi Syndrome","volume":"9","author":"Lozano","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/pcmr.12662","article-title":"Characterization of Melanosomes and Melanin in Japanese Patients with Hermansky\u2013Pudlak Syndrome Types 1, 4, 6, and 9","volume":"31","author":"Okamura","year":"2018","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature11624","article-title":"An Ultraviolet-Radiation-Independent Pathway to Melanoma Carcinogenesis in the Red Hair\/Fair Skin Background","volume":"491","author":"Mitra","year":"2012","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ng0797-289","article-title":"Griscelli Disease Maps to Chromosome 15q21 and Is Associated with Mutations in the Myosin-Va Gene","volume":"16","author":"Pastural","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1172\/JCI200318264","article-title":"Griscelli Syndrome Restricted to Hypopigmentation Results from a Melanophilin Defect (GS3) or a MYO5A F-Exon Deletion (GS1)","volume":"112","author":"Ho","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2141.2009.07888.x","article-title":"Prevalence of Mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in Patients with Severe Congenital Neutropenia","volume":"147","author":"Xia","year":"2009","journal-title":"Br. J. Haematol."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/2\/36\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:53:18Z","timestamp":1760107998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/2\/36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["hematolrep16020036"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16020036","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}